Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value

KKStock As I have written regarding Eli Lilly and Company (NYSE:LLY) beginning in August 2023, I expect the GLP-1 drugs to become the largest sell pharmaceutical class ever, with US sales of $150 billion in 2030. I recently listened to a Grand Rounds presentation on the GLP-1s given at a major medical center. I shall discuss the key comments, which I found to be very useful in understanding both the history of incretins as well as the multi-faceted benefits of this revolutionary drug class. The GLP-1 hor ...